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Abstract
Background: Interferon-α (IFN-α) is one of the central agents in immunotherapy for renal cell
carcinoma (RCC) and binds to the IFN-α receptor (IFNAR). We investigated the role of IFNAR in
RCC.
Methods: We quantified IFNAR mRNA expression in paired tumor and non-tumor samples from
the surgical specimens of 103 consecutive patients with RCC using a real-time reverse transcription
polymerase chain reaction (RT-PCR), and IFNAR2 protein using Western blotting.
Results: The absolute level of IFNAR1 and IFNAR2 mRNAs in tumor and non-tumor tissues did
not correlate with the malignant and metastatic profiles. The relative yields of the PCR product
from the tumor tissue to that from the corresponding non-tumor tissue (T/N) for the expression
of IFNAR mRNAs were calculated. While the T/N ratio of IFNAR1 did not correlate with any
factor, a high T/N ratio of IFNAR2 correlated with poor differentiation (P < 0.05), local invasion (P
< 0.001), and metastasis (P < 0.0001). By multivariate analysis, a high T/N ratio of IFNAR2 predicted
a shortened overall survival in all cases (P < 0.05) and a shorter disease-free survival in those
without metastasis (M0; 68 cases, P < 0.05). Impressively, patients with a poorer response to IFN-
α treatment had a higher IFNAR2 T/N ratio than those who had a good response (P < 0.05).
IFNAR2c protein expression was higher in the primary tumors in patients with metastases (M1; 35
cases) compared to those without ( P < 0.0001).
Conclusion: IFNAR2 is associated with the progression of RCC.
Background
It has been reported that the incidence of renal cell carci-
noma (RCC) is increasing steadily [1]. Although surgical
resection of the primary tumor remains the mainstay of
therapy, RCC is characterized by a high frequency of
metastases at diagnosis or relapse following nephrectomy.
Patients with distant metastases have a poor prognosis,
with a 5-year survival rate of less than 10% [1]. RCC is
notoriously resistant to chemotherapy and radiotherapy
[1-3]. Immunotherapy with interferon-α (IFN-α) achieves
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responses in 10% to 20% of patients with advanced RCC
[1,4]. IFN-α binds to the cell surface IFN-α receptor
(IFNAR), which is composed of two chains, a 110 KDa
subunit (IFNAR1) and a 102 KDa subunit (IFNAR2) [5].
Additionally, three different forms of IFNAR2 have been
reported: a 40 KDa soluble form designated IFNAR2a, a
55 KDa short form known as IFNAR2b, and IFNAR2c, a
102 KDa long form. These different forms are derived
from alternative splicing of the same gene. The IFNAR2c
mediates a biologic response when associated with
IFNAR1 [5]. There have been reports regarding the rela-
tionship between IFNAR expression and human hepato-
celluar carcinoma [6,7]; however, there have been no
published reports on the role of IFNAR in human RCC.
We compared IFNAR mRNA expression in RCC tissues
with non-neoplastic portions of the same resected speci-
men using a real-time reverse transcription-polymerase
chain reaction (RT-PCR), and IFNAR2 protein expression
using Western blotting. The relationship between IFNAR
expression and selected pathologic features of the tumors
was examined. We also assessed whether IFNAR expres-
sion could predict the survival of the patients with these
tumors, and compared its expression in patients treated
with IFN-α who had a good or poor response to therapy.
We postulated that this might predict recurrence.
Methods
Patients and tissue preparation
We studied 103 consecutive Japanese patients (71 men,
32 women), 33 to 81 years old (mean age 63.7 years),
with newly diagnosed clear cell RCC, from 1998 to 2005.
All patients routinely underwent imaging studies (CT
and/or MRI) for preoperative staging prior to radical
nephrectomy. The postoperative follow-up ranged from 2
to 75 months (median, 29 months). Patients underwent
surgery before receiving any other therapy.
For every case, three different tumor sites and varying por-
tions of the non-neoplastic kidney were resected for the
study. The resected tissues were stored at -80°C as
described previously [8-10]. Grading and staging were car-
ried out according to the criteria of the TNM classification
[11]. The study was conducted in accordance with the
Helsinki Declaration. Institutional Review Board approval
was obtained for this investigation. Each patient signed a
consent form approved by the Committee on Human
Rights in Research of our institution.
Systemic postoperative immunotherapy using IFN-α was
usually administered for the patients with pT3/4 tumors,
poor differentiation and/or other organ involvement.
These patients received 3, 5, or 6 million units of natural
human IFN-α intravenously or intramuscularly two or
three times a week for 12 weeks to 6 months, or until
tumor progression. The dosage of IFN-α was decreased for
grade 3/4 toxicity.
Real-time RT-PCR assay
Total RNA was purified from all 103 sets of tumor and
non-tumor RCC tissue samples using the RNA prepara-
tion kit "High Pure RNA Kit" (Roche Diagnostic Ltd, Ger-
many). Total RNA was used as a template for cDNA
synthesis. A 100 µL reaction mixture containing 1 µg of
random hexamers and 100 units of MMLV-reverse tran-
scriptase was incubated at 25°C for 10 min, 42°C for 30
min, and then 99°C for 5 min. The expression profiles of
the IFNAR1 and IFNAR2 genes were analyzed with an ABI
PRISM 7700 Sequence Detection System (Applied Biosys-
tems, Foster City, CA) using the SYBR Green method. The
following specific primers were designed to amplify their
respective genes in all of the primary carcinoma tissues
after confirming their specificities; IFNAR1, sense; 5'-
TGACCAGAAATGAACTGTGTCA-3', anti-sense; 5'-
TTTAAATAGTTAAGAGCTTGCCCG-3'; IFNAR2, sense; 5'-
GAAGGTGGTTAAGAACTGTGC-3', anti-sense; 5'-
CCCGCTGAATCCTTCTAGGACGG-3';  β 2-microglobu-
lin, sense; 5'-ACCCCCACTGAAAAAGATGA-3', anti-sense;
5'-ATCTTCAAACCTCCATGATG). A real-time RT-PCR
assay was performed on a 25 µL reaction mixture contain-
ing 20 ng of sample cDNA, 100 nM sense primer, 100 nM
anti-sense primer, and 12.5 µL of SYBR Green PCR Master
Mix (Applied Biosystems). The PCR was carried out for 45
cycles of 95°C for 15 sec and 60°C for 1 min. To normal-
ize the amplified products in each sample, we used β 2-
microglobulin as a quantitative internal control [9,10]. A
standard curve for each mRNA expression was generated
using five-fold dilutions of a control RNA sample (25×,
5×, 1×, 0.2×, 0.04×). The mRNA expression levels of each
of the 2 targeted genes were presented as a ratio to that of
β 2-microglobulin, and the relative expression levels were
calculated [9,10]. The mean values from the real-time RT-
PCR data for the three samples of the resected tissues were
used for the analysis according to a method described pre-
viously [9,10].
Western blotting assay
Tissue samples were incubated in lysis buffer (50 mM Tris-
HCl, 150 mM NaCl, 1% Nonidet P-40, 1 mg/mL apro-
tinin, and 100 mM Na3VO4) on ice for 30 min. The mix-
ture was centrifuged for 30 min (15,000 rpm, 4°C) and
the supernatant was collected for Western blotting analy-
sis. Samples (50 µg/lane) were electrophoresed in a 10/
20% polyacrylamide muliti-gel 20 (Daiichi Pure Chemi-
cals Co., Ltd., Tokyo, Japan), and transferred to a polyvi-
nylidine difluoride transfer membrane. Membranes were
blocked in 20 mM Tris HCl (pH 7.5) containing 10%-
Broke-Ace and then probed with anti-human IFNAR1 pol-
yclonal antibody (ANOC 4867; a kind gift from Otsuka
Pharmaceutical, Tokushima, Japan) or anti-humanBMC Cancer 2007, 7:159 http://www.biomedcentral.com/1471-2407/7/159
Page 3 of 11
(page number not for citation purposes)
IFNAR2 polyclonal antibody (ANOC 10403; a kind gift
from Otsuka Pharmaceutical, Tokushima, Japan) for 1 h
at room temperature [12,13]. Next, the membranes were
washed several times with 0.1% Triton TBS, and then
incubated with anti-rabbit IgG-HRP antibody (1:1000
dilution; Sigma Chemical, St. Louis, MO) for 1 h. The
reaction was visualized using the ECL system (Amersham
Pharmacia Biotech UK Limited, Buckinghamshire, Eng-
land). Hyperfilm ECL (Amersham Pharmacia Biotech)
was exposed to the membrane, developed, and the inten-
sities of the specific bands were calibrated by NIH image
software. For the quantification of proteins, the relative
amounts of IFNAR2 in the tumors were expressed as a
ratio of the optical density of the bands from the tumor
specimen to those from the corresponding normal tissue;
the latter was set at 1.0 by densitometric analysis as
described previously [8,14]. The mean values from three
experiments were obtained for all the tumor and non-
tumor tissues [8-10,14].
Immunohistochemistry
Immunohistochemistry, using the same specific antibod-
ies as employed for Western blotting [12,13], was per-
formed in 8 tumors with distant metastases (M1) and 8
tumors without (M0) to support the data obtained by
Western blotting as described previously [8].
Statistical analysis
The results of real-time RT-PCR and Western blotting were
analyzed statistically using the Mann-Whitney U test for
two groups as described previously [8,10], and the
Kruskal-Wallis test for three groups. The expression levels
of mRNAs for IFNAR, as well as tumor grade and stage,
were assessed in terms of survival by the Cox proportional
hazards model using univariate and multivariate analyses.
The Kaplan-Meier method was used to estimate survival as
a function of time, and survival differences were assessed
by the log-rank test. P values less than 0.05 were consid-
ered significant. Data were analyzed using commercially
available software.
Results
IFNAR mRNA and protein expression and pathologic 
characteristics
The clinicopathological data are summarized in Table 1.
IFNAR1 and IFNAR2 mRNAs were detected in tumor and
non-tumor kidney specimens. The absolute level of
IFNAR mRNAs ranges wildly due to inter-individual vari-
ations. The absolute level of mRNA expression for IFNAR1
and IFNAR2 in the tumor and non-tumor tissues did not
correlate with the malignant and the metastatic profiles of
the RCC tumors. Since inter-individual variations in the
expression of IFNAR mRNAs may be important, the rela-
Table 1: Clinicopathologic data of the patients
Grade pT Metastasis and 
Sarcomatoid component
IFNa treatment Effect of treatment
M0 (10 acinar) IFNa (-) (10 pts) NED : 10 pts
pT1/2 (12 pts)
Grade 1 (No. of 14 
patients)
M1 (lung meta of 2 acinar) IFNa (+) (2 pts) CR/PR : 1 pt, PD : 1 pt
pT3/4 (2 pts) M0 (2 acinar) IFNa (+) (2 pts) NED : 2 pts
IFNa (-) (35 pts) NED : 32 pts, Meta : 3 pts
M0 (39 acinar)
pT1/2 (45 pts) IFNa (+) (4 pts) NED : 3 pts, Meta : 1 pt
Grade 2 (No. of 57 
patients)
M1 (lung meta of 6 acinar) IFNa (+) (6 pts) CR/PR : 2 pts, PD : 4 pts
IFNa (-) (2 pts) NED : 1 pt, Meta : 1 pt
M0 (7 acinar)
pT3/4 (12 pts) IFNa (+) (5 pts) NED : 4 pts, Meta : 1 pt
M1 (lung meta of 5 acinar) IFNa (+) (5 pts) CR/PR : 2 pts, PD : 3 pts
M0 (5 acinar) IFNa (+) (5 pts) NED : 2 pts, Meta : 3 pts
pT1/2 (15 pts)
M1 (lung meta of 5 acinar IFNa (+) (5 pts) CR/PR : 2 pts, PD : 3 pts
Grade 3 (No. of 32 
patients)
other organs meta in 
addition to lung of 5 
sarcomatoid)
other systemic therapies 
including IFNa
PD : 5 pts
M0 (5 acinar) IFNa (+) (5 pts) NED : 3 pts, Meta : 2 pts
pT3/4 (17 pts)
M1 (lung meta of 5 acinar IFNa (+) (5 pts) PD : 5 pts
other organs meta in 
addition to lung of 7 
sarcomatoid)
other systemic therapies 
including IFNa
PD : 7 ptsBMC Cancer 2007, 7:159 http://www.biomedcentral.com/1471-2407/7/159
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tive yield of the PCR product from the tumor to that from
the corresponding non-tumor tissue (T/N) for expression
of IFNAR1 and IFNAR2 was calculated as previously
[9,10].
There was no relationship between the T/N ratio of
IFNAR1 mRNA and grade (mean ± S.D., grade 1, 0.93 ±
0.35; grade 2, 1.06 ± 0.38; grade 3, 2.51 ± 1.72), stage
(pT1-2, 0.63 ± 0.17; pT3-4, 2.79 ± 2.40), or presence of
metastasis (M0, 1.38 ± 0.41; M1, 5.57 ± 3.86).
In contrast, a increased T/N ratio of IFNAR2 mRNA was
associated with poorer differentiation: grade 1 tumors had
a T/N = 0.32 ± 0.16; grade 2, 1.51 ± 0.54; and grade 3, 9.17
± 2.31, P < 0.0001 (Figure 1A). The T/N ratio of IFNAR2
mRNA also correlated with stage: pT1-2 tumors had a T/N
ratio = 2.75 ± 1.09, while the comparable value for pT3-4
tumors was 5.59 ± 1.41, P < 0.001 (Figure 1B). The T/N
ratio of IFNAR2 was higher in M1 tumors compared to
those in M0 tumors (10.36 ± 2.41 vs. 0.92 ± 0.23, P <
0.0001; Figure 1C).
The T/N ratio of IFNAR2 in tumors (that included a sarco-
matoid component which confers a worse prognosis) was
increased compared to the conventional acinar type
(13.22 ± 4.89 vs. 2.19 ± 0.51, P < 0.0001). There was no
statistical difference in the T/N ratio of IFNAR1 mRNA
between sarcomatoid (4.35 ± 2.45) and conventional aci-
nar type tumors (1.76 ± 0.78, P = 0.133), As shown in
Table 1, 12 patients, including those with a sarcomatoid
component (all patients with grade 3), presented with
metastases at diagnosis.
For further characterization of the expression profiles of
IFNAR2, we also analyzed the expression patterns of both
the IFNAR2b (55 KDa) and IFNAR2c (102 KDa) proteins
using Western blotting analysis (Figure 2). The results of
these experiments revealed that the relative expression lev-
els of IFNAR2b in tumors compared to the corresponding
non-tumor sections, (set to 1.0), did not differ. There was
no significant difference in the expression levels of
IFNAR2c between tumor and non-tumor tissues in cases
without metastasis (M0). Impressively, the IFNAR2c pro-
T (tumor)/N (non-tumor) values of IFNAR2 mRNA expression in kidney Figure 1
T (tumor)/N (non-tumor) values of IFNAR2 mRNA expression in kidney. A; In Grade 1 to 3 tumors. B; In pT1,2 and pT3,4 
tumors. C; In metastasis (+) and (-). D; In effect of treatment of IFN-α (+) and watch-and-see (-). Meta; appearance of meta-
static lesion after nephrectomy. NED; no evidence of disease. CR-PR; complete to partial response. PD; progression of disease. 
The data show the 95%BMC Cancer 2007, 7:159 http://www.biomedcentral.com/1471-2407/7/159
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tein levels were significantly higher in the primary lesions
with distant metastases (M1) (mean ± S.D., 11.29 ± 4.31,
P < 0.0001).
While IFNAR2 proteins were moderately to intensely
expressed in the cytoplasm of cancer cells in the M1 cases,
these proteins were very weakly expressed by immunohis-
tochemistry in normal cells in M1 cases (Figure 3). In M0
cases, the normal cells showed moderate reactions and the
tumor cells showed weak to moderate reactions for
IFNAR2.
IFNAR mRNA expression and survival
The mean values for the T/N ratios of IFNAR1 and IFNAR2
mRNAs in the samples were 3.15 (± 1.69) and 3.33 (±
1.15), respectively. As described previously [8,9], the cases
were divided into two groups (high and low) based upon
whether the expression was above or below this mean.
Comparison of the Kaplan-Meier survival rate plots in
patients with low vs. high expression of IFNAR2 suggested
that a high T/N ratio of IFNAR2 mRNA expression was
associated with a shortened overall survival (P < 0.0001,
Figure 4A). By univariate analysis according to the Cox
Western blotting analyses of IFNAR2 proteins in primary lesions with (M1) and without (M0) metastasis Figure 2
Western blotting analyses of IFNAR2 proteins in primary lesions with (M1) and without (M0) metastasis. IFNAR2b; 55KDa, 
IFNAR2c; 102 KDa. N; non-tumor, T; tumor. Each number corresponds to a case number.BMC Cancer 2007, 7:159 http://www.biomedcentral.com/1471-2407/7/159
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proportional hazards model, overall survival was influ-
enced significantly by grade, stage, cell type, metastasis,
IFNAR1, and IFNAR2 (Table 2). By multivariate analysis,
grade, stage, cell type, metastasis, and IFNAR2 were inde-
pendent prognostic factors (Table 2). Cases of tumors
without distant metastasis at nephrectomy (M0; 68
patients) were divided into those with the T/N ratio of
IRNAR2 mRNA above or below, a mean of 0.92 (± 0.23).
In these localized tumors, Kaplan-Meier plots showed that
a high T/N ratio of IFNAR2 mRNA had a significant influ-
ence on disease-free survival (P  = 0.0112, Figure 4B).
Although grade, stage, and IFNAR2 predicted disease-free
survival in this group in the univariate analyses, stage and
IFNAR2 remained significant in the multivariate analysis
(Table 2). For IFNAR1, with a mean T/N ratio of 0.85 (±
0.16), there was low expression in 43 patients and high
expression in 25 patients, and neither was related to dis-
ease-free survival in these patients.
IFNAR2 mRNA expression and effect of IFN-α
We also compared the T/N ratio of IFNAR2 mRNA with
the effect of IFN-α administration (Figure 1D). Of the M0
cases at nephrectomy (68 patients), the IFNAR2 T/N ratio
in the patients with no evidence of disease (NED) in the
group receiving IFN-α (M0-IFNa(+)/NED; 0.80 ± 0.24)
was higher than those in the untreated group (M0-IFNa(-
)/NED; 0.31 ± 0.07, P = 0.0267). This result was due to the
higher T/N ratio of the M0-IFNa(+)/NED cases with grade
3 and/or pT3/4 cancer. There were no statistical differ-
ences in the IFNAR2 T/N ratio between the patients in
whom a metastatic lesion appeared (lung, bone, liver,
brain, etc.) but was treated with IFN-α (M0-IFNa(+)/Meta;
4.56 ± 1.01) and those left untreated (M0-IFN(-)/Meta;
2.37 ± 0.62). However, the patients with metastatic
lesions had a higher T/N ratio of IFNAR2 mRNA in their
primary tumors (M0-IFNa(+)/Meta and M0-IFN(-)/Meta)
compared with those who had NED after surgery (M0-
IFNa(+)/NED and M0-IFNa(-)/NED, P < 0.001).
In the M1 cases with only lung metastases at time of
nephrectomy (all of conventional acinar type; 23
patients), the IFNAR2 mRNA T/N ratio in the tumors
resistant to IFN-α (M1-IFNa(+)/PD; 11.00 ± 2.18) was
higher than in those for whom it was effective (M1-
IFNa(+)/CR-PR; 1.39 ± 0.22, P = 0.0022). Impressively,
the M0 patients in whom a metastatic lesion appeared
after IFN-α administration (M0-IFNa(+)/Meta) or those
in the wait-and-see group and left untreated (M0-IFNa(-)/
Meta) had higher IFNAR2 T/N ratios compared to the M1
patients who had a good response to IFN-α (M1-IFNa(+)/
CR-PR, P = 0.0058, P = 0.0233, respectively).
Discussion
The absolute level of IFNAR mRNAs ranges wildly due to
inter-individual variations and is not related to their
malignant and metastatic profiles. To take into account
the possibility of inter-individual variations in the expres-
sion of mRNAs and proteins for IFNAR, we compared the
mRNA and protein expressions between paired tumor (T)
and non-tumor (N) kidney samples, and the relative yield
of the PCR product from the tumor to that from the corre-
sponding non-tumor tissue (T/N) for the expression of
IFNAR1 and IFNAR2 mRNAs was calculated as described
previously [9,10]. The T/N ratios of IFNAR1 mRNAs were
not correlated with any clinicopathologic feature. Impres-
sively, high T/N ratios of IFNAR2 mRNA expression in
tumors were associated with poor differentiation, local
invasion, metastasis, shortened survival, and a poorer
response to IFN-α treatment. The protein levels of
IFNAR2c in the primary tumors with synchronous metas-
tases were higher than in those without metastases. To our
knowledge, this is the first report analyzing the relation-
ship between IFNAR and renal cancer.
A previous report found no relationship between type 1
IFNAR expression levels in clear cell RCC tumors and
stage, grade, gender, age or survival [15]. However, our
observation that the relative value of the T/N ratio but not
the absolute level of IFNAR2 mRNA in tumor tissues cor-
related with the malignant and metastatic profiles of
RCCs is puzzling even if there is inter-individual varia-
tions and should be investigated in future studies. The
IFNAR2 mRNA T/N ratio did not correlate with gender or
age.
The prognosis of RCCs with a sarcomatoid component is
poorer than those without such changes (conventional
acinar type), and sarcomatoid RCC is highly resistant to
immunotherapy [1]. In this study, 12 patients with a sar-
comatoid component presented with metastases at diag-
nosis, and their prognosis was very unfavorable in
comparison to those with a conventional acinar type of
RCC. Of the M1 cases, the IFNAR2 mRNA T/N ratio in the
sarcomatoid component (13.22 ± 4.89) was higher than
that in the conventional acinar type (23 patients; 7.22 ±
1.67, P < 0.01, data not shown). Within the non-sarcoma-
toid conventional acinar types, the IFNAR2 mRNA T/N
ratio in the M1 cases (7.22 ± 1.67) was higher than that in
the M0 cases (0.92 ± 0.23, P < 0.0001, data not shown).
Moreover, the IFNAR2 mRNA T/N ratio was associated
with a poorer prognosis not only in overall survival in all
cases but also in disease-free survival in the M0 cases.
Therefore, it appears that IFNAR2 is associated with an
aggressive and high metastatic potential of the cancer
cells. On the other hand, although there was no statistical
difference in the IFNAR1 mRNA T/N ratio between the
sarcomatoid and conventional acinar types of RCC, a
higher IFNAR1 T/N ratio was associated with a poorer
overall survival by univariate analysis. This phenomenon
may be influenced by the poorer survival of sarcomatoidBMC Cancer 2007, 7:159 http://www.biomedcentral.com/1471-2407/7/159
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Immunohistochemistry for IFNAR2 proteins in M1 cases Figure 3
Immunohistochemistry for IFNAR2 proteins in M1 cases. Upper left shows negative staining in normal cells in M1 case (x50). 
Upper right shows strong brown staining in sarcomatoid carcinoma in M1 case (x50). Lower panel shows moderate brown 
staining in clear cell carcinoma with conventional acinar type in M1 case (x200).BMC Cancer 2007, 7:159 http://www.biomedcentral.com/1471-2407/7/159
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types. In fact, the IFNAR1 mRNA T/N ratio had no effect
on disease-free survival in the M0 cases of non-sarcoma-
toidal conventional acinar RCC; however, the possible
role of IFNAR1 in a larger number of sarcomatoid RCC
cases should be examined.
In this study, a higher IFNAR2 mRNA T/N ratio was asso-
ciated with certain metastatic profiles in RCCs. It is impor-
tant to try to distinguish between metachronous bilateral
RCC from a metastasis in the contralateral kidney. A
patient underwent a radical left nephrectomy for a 6 cm,
grade 2 RCC at another hospital in 1995. In 2000 at age
78 years, the patient also underwent a partial right
nephrectomy with a 1 cm surgical margin for another 1.5
cm, grade 1 RCC tumor, and the IFNAR2 mRNA T/N ratio
in the resected tissue was 13.3. The patient was followed
closely without receiving any adjuvant immunotherapy.
In 2002, a metastatic tumor was found that involved the
thyroid gland, and we determined that it also had a high
level of IFNAR2 mRNA expression (1.13 fold more than
the second primary tumor). Since our data indicate that
the IFNAR2 mRNA T/N ratio in grade 1 and pT1a non-sar-
comatoid RCCs is very low, while the T/N ratio in this
patient's second renal tumor was very high, we believe
that the second renal tumor might have been a metastasis
from the left kidney to the right. Accordingly, our data
suggest that even if conventional pathologic studies indi-
cates a low grade and stage RCC, cases with a high IFNAR2
mRNA T/N ratio need to be followed closely and that the
T/N value of IFNAR2 mRNA might be a prognostic factor.
Table 2: Cox regression analysis for various potential prognostic factors in survival
Overall survival (103 patients) Disease-free survival (68 patients) in M0 at Nephrectomy
Variable Unfavora
ble/
favorable 
characteri
stics
No. of 
Patients
Analysis Relative 
risk
95% 
confidenti
al interval
P value No. of 
Patients
Analysis Relative 
risk
95% 
confidenti
al interval
P value
Univariat
e (U)
11.927 4.084 – 
34.864
< 0.0001 U 6.357 2.109 – 
19.163
0.001
Grade 01/02/
2003
32/57/14 17/39/12
Multivaria
te (M)
8.658 1.647 – 
45.529
0.0108 M 1.006 0.175 – 
5.776
0.9942
U 8.305 3.430 – 
32.714
< 0.0001 U 4.691 2.501 – 
13.822
0.002
pT > 3/2 < 31/72 13/55
M 2.171 1.626 – 
7.189
0.0225 M 2.447 1.004 – 
5.965
0.0489
U 9.486 3.479 – 
25.864
< 0.0001
Cell type sarcomat
oid/
12/91 0/68
acinar M 2.773 1.302 – 
9.587
0.017
U 11.798 3.922 – 
35.492
< 0.0001
Metastasi
s
(+)/(-) 35/68 0/68
M 4.362 1.973 – 
19.567
0.026
U 4.267 1.515 – 
12.021
0.006 U 2.028 0.592 – 
6.952
0.2605
IFNAR1 high/low 47/56 25/43
M 1.958 0.661 – 
5.804
0.2252 M 3.244 0.788 – 
13.356
0.1031
U 10.695 4.345 – 
26.323
< 0.0001 U 11.03 2.920 – 
41.655
0.0004
IFNAR2 high/low 35/68 18/50
M 3.813 1.295 – 
11.226
0.0151 M 7.604 1.559 – 
37.101
0.0121BMC Cancer 2007, 7:159 http://www.biomedcentral.com/1471-2407/7/159
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The most commonly used therapy for patients with
advanced RCC has been combined immunotherapy
employing interleukin (IL)-2 and IFN-α in the USA, while
IFN-α is the main agent used in Japan. The question of
who obtains a benefit from immunotherapy with IFN-α is
an important and unanswered question. Although prog-
nostic factors have recently been recognized to aid in this
decision [16], reliable data on immunotherapy using IFN-
α in patients with a poor prognosis, in particular for the
prediction of recurrence in localized RCCs, are lacking.
Recently, Motzer et al. [17] identified five prognostic fac-
tors (Karnofsky performance status, time from diagnosis
of RCC to treatment with IFN-α, serum lactate dehydro-
genese, corrected serum calcium, and hemoglobin) that
correlated with overall survival in patients with metastatic
RCC treated with IFN-α as their initial systemic therapy.
Thus the prognosis of our patients are consistent with
Motzer's model. Furthermore, there is evidence that adju-
vant IFN-α for localized disease is not recommended
unless in specific studies [18]. However, some patients
with grade 3/pT2 M1 tumor had a good response to IFN-
α (M1-IFNa(+)/CR-PR), while an other patient with a
grade 1/pT1 M1 tumor presented with lung metastases
and had resistant disease (M1-IFNa(+)/PD) (Table 1). In
our analysis regarding the relationship between the
IFNAR2 mRNAs T/N ratio and the efficacy of IFN-α
immunotherapy, higher T/N ratios correlated with not
only the likelihood of metastasis and unfavorable progno-
sis but also a poorer response to IFN-α even in the non-
sarcomatoidal conventional acinar RCCs of lower grade
and smaller size (less than 4 cm). These findings might
suggest that M0 patients with a higher IFNAR2 mRNA T/
N ratio might benefit from being treated with IFN-α to
prevent metastasis, and IFN-α would be expected to
decrease the tumor burden in M1 patients with a lower T/
N ratio. These hypotheses should be studied prospectively
in a larger number of patients.
Our data show that there is a upregulation of IFNAR2
mRNAs and IFNAR2c proteins in tumor cells in M1 cases
relative to M0 cases. Upregulation of IFNAR2 in tumor
cells compared to normal cells in the involved kidney
might be advantageous for the anti-cancer effect of IFN-α;
however, there have been no published reports of a direct
relationship between IFNAR2 expression levels and the
effect of externally administered IFN-α. The present study
did not make clear whether upregulation was the cause or
the result of metastasis. We hope our forthcoming study
will clarify this issue.
IFN-α transmits its signals through its homologous recep-
tor complex IFNAR, which is composed of at least two
subunits, IFNAR1 and IFNAR2 [5]. IFNAR2 has been
reported to be the main ligand-binding subunit [5]. In
this study, the IFNAR2 mRNA T/N ratio correlated with
the metastatic profiles in RCC. Because of alternative
splice variants of IFNAR2 mRNA, we confirmed the actual
expression pattern of IFNAR2 by Western blotting analy-
sis. Western blotting analysis showed that the expression
level of IFNAR2c protein was higher in the primary
tumors in comparison with the non-tumor tissues in the
M1 cases but not in M0 cases, indicating that the main
Survival curve in patients with renal cancer based on the  mean values of T/N ratio of expression of IFNAR2 mRNAs in  kidney tissues, the cases were divided into two groups at this  levels – high and low expression Figure 4
Survival curve in patients with renal cancer based on the 
mean values of T/N ratio of expression of IFNAR2 mRNAs in 
kidney tissues, the cases were divided into two groups at this 
levels – high and low expression. Overall survival curve in 
total 103 tumors and disease-free survival curve in MO cases 
of 68 tumors at nephrectomy. P value was analyzed by log-
rank test.BMC Cancer 2007, 7:159 http://www.biomedcentral.com/1471-2407/7/159
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component of IFNAR2 expression was the long form of
IFNAR2c and that IFNAR2c is the important functional
protein associated with the progression of renal cancer.
Recent studies have revealed that the activation of STAT3
and AKT (protein kinase B) are associated with progres-
sion and poor survival in RCCs [19,20]. It has also been
reported that IFNAR2c is responsible for STAT activation
[21,22]. Furthermore, these molecules may play key roles
in cell survival and proliferation in a large number of
human cancers [23]; thus, this pathway may be a molecu-
lar target for cancer therapy. We should elucidate the role
of this pathway in RCCs in a future study.
Our study results are not sufficient for evaluating the util-
ity of IFNAR2 mRNA T/N ratios as a predictable index for
the effect of IFN-α immunotherapy. However, our find-
ings that higher T/N ratios were associated with early
recurrence in organ confined tumors and a poorer
response to IFN-α administration suggest that analyzing
the IFNAR2 mRNA T/N ratios might be useful for predict-
ing prognosis. Although our follow-up period is too short
to draw definitive conclusions and setting a cut-off value
for the IFNAR2 mRNA ratio in order to select patients for
IFN-α immunotherapy may be controversial, we are going
to start a prospective study to assess the utility of IFNAR2
mRNA T/N ratios as a predictor of response to IFN-α
immunotherapy in patients with RCC. A positive result
would substantiate our observations and strengthen their
clinical value.
Conclusion
In this study, the relative value of T/N but not the absolute
level of IFNAR2 mRNA, and IFNAR2c protein in tumor
tissues correlated with the malignant and metastatic pro-
files of RCC.
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